Small molecule · developed by Prelude Therapeutics
PRT13722 is an investigational oral drug given once daily. It is studied in hormone-receptor-positive, HER2-negative breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07905001 | Phase 1 | Breast Cancer | Recruiting | PRLD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Breast CancerHER2-negative Breast CancerHormone-receptor-positive Breast CancerHR-positive Breast CancerHR+/HER2- Breast CancerLocally Advanced Breast CancerMetastatic Breast Cancer
Updated Nov 15, 2026. Something wrong or missing? Report it on the PRLD page.
See PRLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PRLD catalysts and pipeline →